Zai Lab Ltd (ZLAB)

Currency in USD
36.82
-0.98(-2.59%)
Closed·
After Hours
36.820.00(0.00%)
·
ZLAB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 5 days
Fair Value
Day's Range
35.5537.01
52 wk Range
16.0144.34
Key Statistics
Prev. Close
37.8
Open
36.22
Day's Range
35.55-37.01
52 wk Range
16.01-44.34
Volume
602.75K
Average Volume (3m)
913.86K
1-Year Change
99.67%
Book Value / Share
7.43
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ZLAB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
56.65
Upside
+53.86%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Zai Lab Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Zai Lab Ltd Company Profile

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company’s oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam. The company was incorporated in 2013 and is headquartered in Pudong, China.

Employees
1869

Compare ZLAB to Peers and Sector

Metrics to compare
ZLAB
Peers
Sector
Relationship
P/E Ratio
−16.2x−2.7x−0.5x
PEG Ratio
−0.560.000.00
Price/Book
5.0x1.8x2.6x
Price / LTM Sales
9.7x19.0x3.2x
Upside (Analyst Target)
52.0%316.7%45.7%
Fair Value Upside
Unlock4.3%8.6%Unlock

Analyst Ratings

11 Buy
1 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 56.65
(+53.86% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.04 / -0.46
Revenue / Forecast
106.49M / 113.77M
EPS Revisions
Last 90 days

ZLAB Income Statement

People Also Watch

44.430
SMR
-11.51%
168.10
CRCL
-8.40%
15.400
IREN
-4.41%
17.160
JOBY
+3.00%
104.14
CRWV
-8.75%

FAQ

What Stock Exchange Does Zai Lab Trade On?

Zai Lab is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Zai Lab?

The stock symbol for Zai Lab is "ZLAB."

What Is the Zai Lab Market Cap?

As of today, Zai Lab market cap is 4.07B.

What Is Zai Lab's Earnings Per Share (TTM)?

The Zai Lab EPS (TTM) is -2.48.

When Is the Next Zai Lab Earnings Date?

Zai Lab will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is ZLAB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Zai Lab Stock Split?

Zai Lab has split 0 times.

How Many Employees Does Zai Lab Have?

Zai Lab has 1869 employees.

What is the current trading status of Zai Lab (ZLAB)?

As of 02 Aug 2025, Zai Lab (ZLAB) is trading at a price of 36.82, with a previous close of 37.80. The stock has fluctuated within a day range of 35.55 to 37.01, while its 52-week range spans from 16.01 to 44.34.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.